Hydroxychloroquine treatment for Recurrent Pregnancy Loss: a randomized double-blind placebo-controlled trial

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-515579-36-00

Enrollment

186

Registered

2024-07-25

Start date

2017-04-12

Completion date

Unknown

Last updated

2025-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Pregnancy Loss

Brief summary

The trial will conclude after the inclusion and follow-up (pregnancy loss or 6 months after live birth) for 186 women. Included women who become pregnant less than two months after starting the medication or do not achieve pregnancy within one year of starting the medication will be replaced 1:1 by new patients included in the trial.

Interventions

DRUGPlaquenil

DRUGfilmovertrukne tabletter

DRUGLactose monohydrate

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
The trial will conclude after the inclusion and follow-up (pregnancy loss or 6 months after live birth) for 186 women. Included women who become pregnant less than two months after starting the medication or do not achieve pregnancy within one year of starting the medication will be replaced 1:1 by new patients included in the trial.	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026